ABOUT THIS SITE.

Buy Ipamorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on ipamorelin (NNC 26-0161). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The domain modifier "buy" is editorial framing — a position the publisher occupies relative to the researcher community that searches for sourcing and quality-assurance information. It is not a claim about the site's services. This site does not sell ipamorelin or any other compound. Every page of this site carries the disclosure: For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.

When researchers search for ipamorelin, many are looking for sourcing information: what purity specifications to require, what COA documentation to request, how the compound has been characterized analytically in the published literature. This site answers those questions from the peer-reviewed record — not from vendor marketing. The sourcing standards described on /dosage reflect what the published pharmacological literature and the FDA 503A compounding nomination docket (FDA-2024-N-4188) specify; they are editorial guidance from the science, not endorsements of any specific supplier.

Every quantitative claim on this site is sourced to a specific peer-reviewed publication, regulatory docket, or official anti-doping record. Inline [N] citation markers throughout the site link to the full reference in /references. PubMed links and DOIs are provided for every primary literature citation to enable independent verification.

We do not paraphrase manufacturer claims, supplier marketing, or forum anecdote. The research record for ipamorelin is clear about its limitations — one Phase 2 human trial that did not reach statistical significance on its primary endpoint, virtually all mechanistic data from rodent models, a withdrawn FDA compounding nomination, and WADA S2.2.4 prohibition — and this site presents those limitations directly rather than omitting them.

We do not write prescriptive language. The site describes what was studied in published research and what the regulatory record shows; it does not recommend doses, routes, or uses for any compound. Third-person, study-attributed language is used throughout: "In adult female rats at 100 mcg/kg three times daily" rather than "take 100 mcg three times daily."

Content is updated when new peer-reviewed data are published. The current citation record covers studies from 1998 through 2025, including three recent additions: a 2024 Physiology & Behavior cisplatin-ferret weight loss study, a 2025 Preprints.org musculoskeletal review, and a 2025 Anticancer Research GHS class review.